Latest Conference Articles

New research reveals that preoperative breast MRI does not enhance outcomes for early-stage breast cancer patients, challenging its routine use in treatment plans.

New trial data reveals that combining preoperative radiation with pembrolizumab enhances immune response in high-risk, early-stage breast cancer patients.

Abemaciclib shows promise as a monotherapy for HR-positive, HER2-negative breast cancer after CDK4/6 inhibitor failure, benefiting 33% of patients.

Sacituzumab govitecan enhances quality of life for untreated advanced TNBC patients, despite increased gastrointestinal toxicities compared to chemotherapy.

The FDA reviews nivolumab with chemotherapy as a potential new frontline treatment for advanced classical Hodgkin lymphoma, promising improved outcomes.

Subgroup analyses reveal T-DXd significantly improves invasive disease-free survival in early-stage HER2-positive breast cancer compared to T-DM1, regardless of HER2 expression.

A recent study reveals critical insights on disease progression and survival rates in patients with relapsed/refractory large B-cell lymphoma treated with bispecific antibodies.

Tucatinib enhances frontline maintenance therapy for HER2-positive metastatic breast cancer, significantly improving progression-free survival compared to placebo.

An innovative AI model enhances breast cancer recurrence predictions, outperforming traditional methods and offering tailored treatment insights for patients.

Patients in the DESTINY-Breast09 trial report improved quality of life with T-DXd plus pertuzumab, highlighting distinct side effect profiles compared to standard care.

New data reveals that the BPd treatment combination significantly improves outcomes in relapsed multiple myeloma, outperforming traditional therapies.

A phase 2 study reveals promising efficacy and safety of TKI and inotuzumab ozogamicin therapy for newly diagnosed Ph+ ALL, achieving high response rates.

Giredestrant shows significant improvement in invasive disease-free survival for early breast cancer patients, outperforming standard endocrine therapy in a pivotal trial.

Aromatase inhibitors enhance disease-free survival in HR+/HER2+ early breast cancer, outperforming SERMs without compromising overall survival, according to ALTTO trial findings.

The MonumenTAL-2 study reveals promising results for talquetamab and pomalidomide in treating relapsed/refractory multiple myeloma, showcasing high response rates.

Researchers explore the safety and efficacy of consolidating cevostamab with BCMA CAR T therapy for relapsed multiple myeloma, highlighting management protocols.

New research reveals mismatched unrelated donors significantly improve transplant outcomes, expanding options for diverse patients in need of life-saving procedures.

KLN-1010 shows promising MRD-negative responses in relapsed/refractory multiple myeloma patients, highlighting its potential as a safe, off-the-shelf CAR T therapy.

The LimiTEC trial reveals that discontinuing teclistamab after 6-9 months yields comparable outcomes to continuous treatment in multiple myeloma patients.

Discover the most anticipated breast cancer abstracts at the 2025 San Antonio Symposium, featuring groundbreaking studies in HR+, HER2+, and TNBC.

XmAb819 shows promising antitumor activity and manageable safety in clear cell renal cell carcinoma patients, highlighting its potential in future therapies.

A 6-month complete response predicts improved long-term survival in high-risk large B-cell lymphoma patients treated with axicabtagene ciloleucel.

Dexamethasone prophylaxis significantly reduces severe neurotoxicity in LBCL patients receiving axi-cel, enhancing safety without compromising efficacy.

Discover how a remote therapeutic monitoring system enhances patient care and streamlines clinic operations, reducing hospitalizations for hematologic malignancies.

A phase 1b/2 trial reveals MK-1045 shows manageable safety and promising efficacy in treating relapsed/refractory B-cell acute lymphoblastic leukemia.

Remote therapeutic monitoring significantly lowers infection-related hospitalizations in hematological cancer patients, enhancing outpatient care and reducing emergency visits.

The MANIFEST-2 trial reveals that pelabresib combined with ruxolitinib significantly improves outcomes for myelofibrosis patients compared to standard treatments.

New data from the SEQUOIA trial highlights the effectiveness of zanubrutinib and venetoclax in achieving high progression-free survival rates in CLL/SLL patients.